Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-06-26
2007-06-26
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S345000, C435S069100
Reexamination Certificate
active
11493687
ABSTRACT:
A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
REFERENCES:
patent: 5801042 (1998-09-01), Chang et al.
patent: 5849564 (1998-12-01), Chang et al.
patent: 5854398 (1998-12-01), Chang et al.
patent: 5861500 (1999-01-01), Chang et al.
patent: 5948676 (1999-09-01), Chang et al.
patent: WO 98/03657 (1998-01-01), None
patent: WO 98/04576 (1998-02-01), None
Aoki et al., Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6,Blood93(12):4034-4043 (1999).
Aoki et al., Detection of viral interleukin-6 in Karposi's sarcoma-associated herpesvirus-linked diseases.Blood94(10):431a (1999) (Abstract only).
Aoki et al., Indentification of unique binding site for gp130 in viral interleukin-6 encoded by human herpesvirus 8,Blood96(11):572a (2000) (Abstract only).
Aoki et al., Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders,Blood97(7):2173-2176 (2001).
Aoki et al., Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.Blood97(8):2526-2527 (2001).
Asou et al., Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells,Blood91(7):2475-2481 (1998).
Brakenhoff et al., Development of a human interleukin-6 receptor antagonist,Journal of Biological Chemistry369(1):86-93 (1994).
Burger et al., Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells,Blood91(6):1858-1863 (1998).
Chow et al., Structure of an extracellular gp130 cytokine receptor signaling complex,Science291:2150-2155 (2001).
Drexler et al., Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines,Leukemia13(4):634-640 (1999) (Abstract only).
Hideshima et al., Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6,Clinical Cancer Research6:1180-1189 (2000).
Hoischen et al., Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells,Eur. J. Biochem. 267:3604-3612 (2000).
Jones et al., Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells,Blood94(8):2871-2879 (1999).
Molden et al., A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit,Journal of Biological Chemistry272(31) 19625-19631 (1997).
Moore et al., Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV,Science274(5293):1739-1744 (2000).
Aoki Yoshiyasu
Tosato Giovanna
Klarquist & Sparkman, LLP
Salimi Ali R.
The Government of the United States of America as represented by
LandOfFree
Specific binding agents for KSHV vIL-6 that neutralize a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Specific binding agents for KSHV vIL-6 that neutralize a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific binding agents for KSHV vIL-6 that neutralize a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3854842